Design and development of novel cyclosporine A lipid nanoparticle formulations appropriate for oral delivery
Autor(es) : 
Palabras clave : 
Materias Investigacion::Ciencias de la Salud
nanoparticle
microparticle
immunosuppressant
drug delivery system
cyclosporine A
Fecha de publicación: 
2016
Fecha de la defensa: 
16-feb-2016
Cita: 
GUADA, Melissa. “Design and development of novel cyclosporine A lipid nanoparticle formulations appropriate for oral delivery”. Dios Vieitez, M. C. y Blanco Prieto, M. J. (dir.). Tesis doctoral. Universidad de Navarra, Pamplona, 2016
Resumen
Cyclosporine A (CsA) is a well-known immunosuppressive agent that gained considerable importance in transplant medicine in the late 1970s due to its selective and reversible inhibition of T-lymphocytes. While CsA has been widely used to prevent graft rejection in patients undergoing organ transplant it was also used to treat several systemic and local autoimmune disorders. Currently, the neuro- and cardio-protective effects of CsA (CiCloMulsion®; NeuroSTAT®) are being tested in phase II and III trials respectively and NeuroSTAT® received orphan drug status from US FDA and Europe in 2010. The reformulation strategies focused on developing Cremophor® EL free formulations and address variable bioavailability and toxicity issues of CsA. This review is an attempt to highlight the progress made so far and the room available for further improvements to realize the maximum benefits of CsA.

Ficheros en este registro:
Fichero: 
TESIS_M_GUADAsinart.pdf
Descripción: 
Tamaño: 
4,41 MB
Formato: 
Adobe PDF


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.